PIQ Stock Overview
Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Proteomics International Laboratories Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.61 |
| 52 Week High | AU$1.40 |
| 52 Week Low | AU$0.55 |
| Beta | 0.38 |
| 1 Month Change | -10.87% |
| 3 Month Change | -6.11% |
| 1 Year Change | -37.88% |
| 3 Year Change | -51.95% |
| 5 Year Change | 136.54% |
| Change since IPO | 173.33% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable
Nov 16
Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ)
Sep 29We're Hopeful That Proteomics International Laboratories (ASX:PIQ) Will Use Its Cash Wisely
May 10Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being
Nov 17Is Proteomics International Laboratories (ASX:PIQ) In A Good Position To Invest In Growth?
Aug 09Shareholder Returns
| PIQ | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | -1.6% | -2.1% | -3.1% |
| 1Y | -37.9% | -10.3% | 6.7% |
Return vs Industry: PIQ underperformed the Australian Life Sciences industry which returned -6% over the past year.
Return vs Market: PIQ underperformed the Australian Market which returned 7.5% over the past year.
Price Volatility
| PIQ volatility | |
|---|---|
| PIQ Average Weekly Movement | 9.6% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in AU Market | 16.4% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: PIQ has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PIQ's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Richard Lipscombe | www.proteomics.com.au |
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment.
Proteomics International Laboratories Ltd Fundamentals Summary
| PIQ fundamental statistics | |
|---|---|
| Market cap | AU$80.57m |
| Earnings (TTM) | -AU$6.38m |
| Revenue (TTM) | AU$3.28m |
24.6x
P/S Ratio-12.6x
P/E RatioIs PIQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PIQ income statement (TTM) | |
|---|---|
| Revenue | AU$3.28m |
| Cost of Revenue | AU$2.02m |
| Gross Profit | AU$1.26m |
| Other Expenses | AU$7.64m |
| Earnings | -AU$6.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 38.49% |
| Net Profit Margin | -194.62% |
| Debt/Equity Ratio | 0% |
How did PIQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 08:28 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Proteomics International Laboratories Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Iain Wilkie | Morgans Financial Limited |